The global virus filtration market was valued at approximately USD 4.6 billion in 2023. The market is anticipated to grow at a robust CAGR of 12.3% during the forecast period of 2024-2032, reaching an estimated value of USD 13 billion by 2032. Theis growth is primarily driven by the rising population, the increased demand for biopharmaceutical drugs, and the growing prevalence of chronic diseases.
Growing Biopharmaceutical Industry: The global biopharmaceutical industry is experiencing rapid growth, fuelled by advancements in biotechnology and a growing pipeline of biologic drugs. Virus filtration is a critical component in the manufacturing process of these drugs, ensuring that they meet stringent safety standards. This growth is directly contributing to the increased adoption of virus filtration systems.
Increasing Focus on Safety in Blood Products: The safety of blood and blood products is of utmost importance, and virus filtration plays a critical role in removing viral contaminants from these products. The growing demand for safe blood products, driven by increasing surgical procedures and the prevalence of blood-related disorders, is propelling the market for virus filtration.
Expansion of Gene and Cell Therapies: The emergence of advanced therapies, such as gene and cell therapies, has created a significant demand for virus filtration systems. These therapies often involve the use of viral vectors, making virus filtration an essential step in ensuring the safety and efficacy of the final product.
Regulatory Compliance: While stringent regulations drive the market, they also pose a challenge for manufacturers. Ensuring compliance with varying regulatory standards across different regions can be resource-intensive and time-consuming, potentially delaying product approvals and market entry.
High Operational Costs: Implementing and maintaining virus filtration systems involves substantial operational costs, including the procurement of advanced filtration technologies, regular system validation, and skilled personnel to manage the processes. These high operational costs can be a barrier, especially for smaller biopharmaceutical companies, limiting their ability to invest in these critical systems and impacting the overall market growth.
Increased Adoption of Single-Use Technologies: The biopharmaceutical industry is increasingly adopting single-use technologies for manufacturing, which offer flexibility, cost savings, and reduced risk of cross-contamination. Virus filtration systems that are compatible with single-use formats are likely to see increased demand, presenting a growth opportunity for market players.
Rising Demand for Personalised Medicine: The growing trend towards personalised medicine, which involves the development of tailored therapies based on individual patient profiles, is creating new opportunities for virus filtration. As personalised therapies become more prevalent, the need for precise and reliable filtration processes will drive market growth.
Increasing Focus on Sustainability: Sustainability is becoming a key consideration in biopharmaceutical manufacturing, with companies seeking to reduce their environmental footprint. Virus filtration systems that are designed to minimise waste and energy consumption are aligning with this trend, driving demand for eco-friendly solutions.
Adoption of Automation and Digitalisation: The adoption of automation and digitalisation in biopharmaceutical manufacturing is transforming virus filtration processes. Automated filtration systems, equipped with advanced monitoring and control capabilities, are enhancing process efficiency and consistency, contributing to the market's growth.
Growth in Contract Manufacturing Organisations (CMOs): The outsourcing of biopharmaceutical manufacturing to CMOs is on the rise, driven by the need for cost-effective production solutions and the desire to focus on core competencies. CMOs are increasingly investing in virus filtration systems to meet the stringent quality requirements of their clients, boosting the market.
Expansion of Bioprocessing Capacity: The global bioprocessing capacity is expanding rapidly, with new facilities being established to meet the growing demand for biologics. This expansion is driving the demand for virus filtration systems, which are essential components in bioprocessing operations.
Development of Multi-Product Facilities: Biopharmaceutical manufacturers are increasingly developing multi-product facilities to maximise their production capabilities. Virus filtration systems that offer versatility and can handle multiple products are in high demand as manufacturers seek to optimise their operations.
This product will be delivered within 5-7 business days.
Global Virus Filtration Market- Analysis
Virus filtration is essential in biopharmaceutical manufacturing, ensuring the safety and efficacy of products by removing viral contaminants. It is crucial for applications such as vaccines, blood products, and gene therapies. Virus filtration systems, employing advanced technologies like nanofiltration and ultrafiltration, are designed to selectively retain viruses while preserving the integrity of the final product. The increasing demand for biologics and heightened focus on product safety are driving the global adoption of these systems, making them vital in producing safe and effective biopharmaceuticals.Market Drivers
Rising Prevalence of Chronic Diseases: The increasing prevalence of chronic diseases, such as cancer, diabetes, and autoimmune disorders, is driving the demand for biologics, which in turn, is boosting the need for virus filtration systems. As the production of biologics expands to meet the growing patient needs, the requirement for effective virus filtration to ensure product safety becomes paramount.Growing Biopharmaceutical Industry: The global biopharmaceutical industry is experiencing rapid growth, fuelled by advancements in biotechnology and a growing pipeline of biologic drugs. Virus filtration is a critical component in the manufacturing process of these drugs, ensuring that they meet stringent safety standards. This growth is directly contributing to the increased adoption of virus filtration systems.
Increasing Focus on Safety in Blood Products: The safety of blood and blood products is of utmost importance, and virus filtration plays a critical role in removing viral contaminants from these products. The growing demand for safe blood products, driven by increasing surgical procedures and the prevalence of blood-related disorders, is propelling the market for virus filtration.
Expansion of Gene and Cell Therapies: The emergence of advanced therapies, such as gene and cell therapies, has created a significant demand for virus filtration systems. These therapies often involve the use of viral vectors, making virus filtration an essential step in ensuring the safety and efficacy of the final product.
Market Challenges
Complexity of Biopharmaceutical Manufacturing: Virus filtration is just one of the many complex steps involved in biopharmaceutical manufacturing. The integration of virus filtration into existing manufacturing processes can be challenging, requiring significant expertise and resources. This complexity can slow down the adoption of virus filtration technologies.Regulatory Compliance: While stringent regulations drive the market, they also pose a challenge for manufacturers. Ensuring compliance with varying regulatory standards across different regions can be resource-intensive and time-consuming, potentially delaying product approvals and market entry.
High Operational Costs: Implementing and maintaining virus filtration systems involves substantial operational costs, including the procurement of advanced filtration technologies, regular system validation, and skilled personnel to manage the processes. These high operational costs can be a barrier, especially for smaller biopharmaceutical companies, limiting their ability to invest in these critical systems and impacting the overall market growth.
Future Opportunities
Technological Advancements in Filtration: Ongoing advancements in virus filtration technologies, such as the development of new materials and membrane designs, are creating opportunities for enhanced filtration efficiency and cost-effectiveness. These innovations are expected to drive market growth by offering improved solutions for biopharmaceutical manufacturing.Increased Adoption of Single-Use Technologies: The biopharmaceutical industry is increasingly adopting single-use technologies for manufacturing, which offer flexibility, cost savings, and reduced risk of cross-contamination. Virus filtration systems that are compatible with single-use formats are likely to see increased demand, presenting a growth opportunity for market players.
Rising Demand for Personalised Medicine: The growing trend towards personalised medicine, which involves the development of tailored therapies based on individual patient profiles, is creating new opportunities for virus filtration. As personalised therapies become more prevalent, the need for precise and reliable filtration processes will drive market growth.
Global Virus Filtration Market Trends
Shift Towards Continuous Manufacturing: The biopharmaceutical industry is gradually shifting towards continuous manufacturing processes, which offer advantages in terms of efficiency, cost savings, and product quality. Virus filtration systems that can be integrated into continuous manufacturing workflows are gaining traction as the industry moves away from traditional batch processes.Increasing Focus on Sustainability: Sustainability is becoming a key consideration in biopharmaceutical manufacturing, with companies seeking to reduce their environmental footprint. Virus filtration systems that are designed to minimise waste and energy consumption are aligning with this trend, driving demand for eco-friendly solutions.
Adoption of Automation and Digitalisation: The adoption of automation and digitalisation in biopharmaceutical manufacturing is transforming virus filtration processes. Automated filtration systems, equipped with advanced monitoring and control capabilities, are enhancing process efficiency and consistency, contributing to the market's growth.
Growth in Contract Manufacturing Organisations (CMOs): The outsourcing of biopharmaceutical manufacturing to CMOs is on the rise, driven by the need for cost-effective production solutions and the desire to focus on core competencies. CMOs are increasingly investing in virus filtration systems to meet the stringent quality requirements of their clients, boosting the market.
Expansion of Bioprocessing Capacity: The global bioprocessing capacity is expanding rapidly, with new facilities being established to meet the growing demand for biologics. This expansion is driving the demand for virus filtration systems, which are essential components in bioprocessing operations.
Development of Multi-Product Facilities: Biopharmaceutical manufacturers are increasingly developing multi-product facilities to maximise their production capabilities. Virus filtration systems that offer versatility and can handle multiple products are in high demand as manufacturers seek to optimise their operations.
Global Virus Filtration Market Segmentation
Market Breakup by Product
- Kits and Reagents
- Virus Filtration Systems
- Services
Market Breakup by Application
- Medical Devices
- Water Purification
- Air Purification
- Biological
- Vaccines and Therapeutics
- Blood and Blood Products
- Cellular and Gene Therapy Products
- Tissue and Tissue Products
- Others
Market Breakup by End User
- Pharmaceutical and Biotechnology Companies
- Contract Research Organization
- Academic and Research Institutes
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Virus Filtration Market Competitive Landscape
The competitive landscape of the global virus filtration market is highly dynamic, featuring prominent players such as Asahi Kasei Medical Co. Ltd, Charles River Laboratories International Inc., Sartorius AG, and Qiagen NV, Pall Corporation, Merck KgaA, General Electricity Company, Thermo fisher Scientific Inc., Lonza Group Ltd., Clean Biologics Group, Texcell SA, Rad Source Technologies Inc. These companies are actively engaged in mergers and acquisitions, driving market consolidation and expansion. Significant investments in research and development are central to their strategies, with a focus on innovating and enhancing the efficiency of virus filtration technologies. Frequent new product launches are made in response to evolving industry needs and regulatory requirements, while strategic partnerships are common, allowing companies to leverage each other's strengths in distribution, technology, and market reach. This competitive environment is characterised by continuous technological advancements and efforts to expand global market presence, supporting the overall growth of the virus filtration market.Key Questions Answered in the Report
- What is the current and projected market size of the global virus filtration market?
- What are the primary drivers propelling the growth of the virus filtration market?
- What challenges are manufacturers facing in the virus filtration market, particularly regarding regulatory compliance?
- How are technological advancements influencing the efficiency and adoption of virus filtration systems?
- What role does the rising prevalence of chronic diseases play in the increasing demand for virus filtration?
- How is the expansion of gene and cell therapies impacting the demand for virus filtration systems?
- What opportunities are emerging from the adoption of single-use technologies in the virus filtration market?
- How is the shift towards continuous manufacturing processes affecting the virus filtration market?
- Why do kits and reagents dominate the virus filtration market in terms of product segmentation?
- What is driving the rapid growth of the virus filtration market in the Asia Pacific region?
- How are strategic partnerships and mergers influencing the competitive landscape of the virus filtration market?
- What are the implications of high operational costs on the adoption of virus filtration technologies by smaller biopharmaceutical companies?
Key Benefits for Stakeholders
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the global virus filtration market from 2017-2032.- The research report provides the latest information on the market drivers, challenges, and opportunities in the global virus filtration market.
- The study maps the leading, as well as the fastest-growing, regional markets, enabling stakeholders to identify key country-level markets within each region.
- Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyse the level of competition within the global virus filtration industry and its attractiveness.
- The competitive landscape section allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
This product will be delivered within 5-7 business days.
Table of Contents
1 Preface
3 Global Virus Filtration Market Overview
4 Vendor Positioning Analysis
5 Global Virus Filtration Market Landscape*
6 Global Virus Filtration Market Dynamics
7 Global Virus Filtration Market Segmentation (2017-2032)
8 North America Virus Filtration Market (2017-2032)
9 Europe Virus Filtration Market (2017-2032)
10 Asia Pacific Virus Filtration Market (2017-2032)
11 Latin America Virus Filtration Market (2017-2032)
12 Middle East and Africa Virus Filtration Market (2017-2032)
13 Patent Analysis
14 Funding and Investment Analysis
15 Strategic Initiatives
16 Supplier Landscape
17 Global Virus Filtration Market - Distribution Model (Additional Insight)
Companies Mentioned
- Asahi Kasei Medical Co. Ltd
- Charles River Laboratories International Inc.
- Sartorius AG
- Qiagen NV
- Pall Corporation.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 200 |
Published | October 2024 |
Forecast Period | 2024 - 2032 |
Estimated Market Value ( USD | $ 5.1 Billion |
Forecasted Market Value ( USD | $ 13 Billion |
Compound Annual Growth Rate | 12.3% |
Regions Covered | Global |
No. of Companies Mentioned | 5 |